Articles by Patrick Daly
NX-5948 showed tolerable safety and promising responses in patients with relapsed or refractory CLL or non-Hodgkin lymphoma.
Brigatinib showed promising responses in patients with ALK-positive anaplastic large-cell lymphoma after brentuximab vedotin.
Drs. Mehta-Shah and Horwitz comment on the lessons to be learned from the reanalysis of the Ro-CHOP trial.
Adding romidepsin to CHOP improved PFS in patients with peripheral T-cell lymphoma after long-term follow-up.
James Berenson, MD, of the Berenson Cancer Center, discusses the launch of the Myeloma BioBank.
Dr. Oluwole discussed new data on brexu-cel in patients with relapsed or refractory ALL.
The US FDA approved blinatumomab for the treatment of CD19-positive, Philadelphia chromosome-negative B-cell precursor ALL.
Dr. Rodríguez-Otero shares the MRD analysis from the phase III PERSEUS trial at the 2024 ASCO Annual Meeting.
Dr. Pemmaraju discusses three major unanswered questions for myeloproliferative neoplasm researchers.
Compared with epoetin alfa, luspatercept more frequently yielded improvements in anemia measures in lower-risk MDS.
Drs. Winer, Daver, and Abaza share their thoughts on the next major breakthroughs in the treatment of AML.
Treatment with liso-cel was promising in patients with relapsed or refractory follicular lymphoma in TRANSCEND FL.
Drs. Winer, Daver, and Abaza share their thoughts and experiences with emavusertib in patients with AML.
ESA treatment after red blood cell transfusions was associated with worse survival compared with ESAs prior to transfusions.
Drs. Winer, Daver, and Abaza discuss the major breakthroughs in the treatment of acute myeloid leukemia.
Venetoclax and obinutuzumab with or without ibrutinib improved PFS versus chemoimmunotherapy or venetoclax and rituximab.
Drs. Winer, Abaza, and Daver discuss their own treatment strategies for patients with AML.
A reduced venetoclax exposure of seven days was comparable with continual venetoclax exposure in patients with AML.
MPN depend on mutated JAK signaling, and targeting the mutations suppressed disease features and improved overall survival.
Pelabresib plus ruxolitinib improved spleen and symptom responses in JAKi-naïve patients with myelofibrosis.
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC. All rights reserved.